Evaluation of lymph node virus burden in human immunodeficiency virus- infected patients receiving efavirenz-based protease inhibitor-sparing highly active antiretroviral therapy

Journal of Infectious Diseases

Volumn 181, Issue 4, 2000, Pages 1273-1279

  Dybul, Mark ^a   Chun, Tae Wook ^a   Ward, Douglas J ^d   Hertogs, Kurt ^f   Larder, Brendan ^g   Fox, Cecil H ^b   Orenstein, Jan M ^e   Baird, Barbara F ^h   Li, Yuexia ^c   Green, Linda G ^d   Engel, Delphine ^a   Liu, Shuying ^h   Mican, JoAnn M ^h   Fauci, Anthony S ^a  

^a NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES   (United States)

^b Molecular Histology Laboratories   (United States)

^c Advanced Bioscience Laboratories   (United States)

^d GEORGE WASHINGTON UNIVERSITY   (United States)

^e GEORGE WASHINGTON UNIVERSITY SCHOOL OF MEDICINE AND HEALTH SCIENCES   (United States)

^f Virco BVBA   (Belgium)

^g Virco UK Ltd   (United Kingdom)

^h NONE

Author keywords

[No Author keywords available]

Indexed keywords

EFAVIRENZ; INDINAVIR; LAMIVUDINE; NELFINAVIR; STAVUDINE; VIRUS RNA; ZIDOVUDINE;

ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG EFFICACY; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; LYMPH NODE; NUCLEOTIDE SEQUENCE; PRIORITY JOURNAL; TREATMENT OUTCOME; VIRUS LOAD; VIRUS REPLICATION;

ANTI-HIV AGENTS; COCULTURE TECHNIQUES; CROSS-SECTIONAL STUDIES; GENOTYPE; HIV; HIV INFECTIONS; HUMANS; IN SITU HYBRIDIZATION; LYMPH NODES; OXAZINES; PROTEASE INHIBITORS; REVERSE TRANSCRIPTASE INHIBITORS; RNA, VIRAL; VIRAL LOAD; VIRUS REPLICATION;

EID: 0034103473     PISSN: 00221899     EISSN: None     Source Type: Journal    
DOI: 10.1086/315407     Document Type: Article

References (31)

1. 1. Centers for Disease Control and Prevention. Report of the NIH panel to define principles of therapy of HIV infection and guidelines for the use of antiretroviral agents in HIV-infected adults and adolescents. MMWR Morb Mortal Wkly Rep 1998; 47:1-82.
2. 2. Kopp JB, Miller KD, Mican JA, et al. Crystalluria and urinary tract abnormalities associated with indinavir [see comments]. Ann Intern Med 1997; 127:119-25.
3. 3. Behrens G. Dejam A, Schmidt H, et al. Impaired glucose tolerance, beta cell function and lipid metabolism in HIV patients under treatment with protease inhibitors. AIDS 1999; 13:F63-70.
4. 4. Miller KD, Jones E, Yanovski JA, Shankar R, Feuerstein I, Falloon J. Visceral abdominal-fat accumulation associated with use of indinavir. Lancet 1998; 351:871-5.
5. 5. Schechter M, Struchiner CJ, Harrison LH. Protease inhibitors as initial therapy for individuals with an intermediate risk of HIV disease progression: is more necessarily better? AIDS 1999; 13:97-102.
6. 6. Manion D, Faulkner E, Saxton TD, et al. Durability of response of efavirenz-containing regimens: report of the post-control period results of studies with EFV. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1999.
7. 7. Manion D, Labriola DF, Ruiz NM. Efficacy of efavirenz containing regimens in patients with baseline plasma HIV-RNA viral loads exceeding 100,000 copies/mL. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1999.
8. 8. Natarajan V, Bosche M, Metcalf JA, Ward DJ, Lane HC, Kovacs JA. HIV-1 replication in patients with undetectable plasma virus receiving HAART. Lancet 1999; 353:119-20.
9. 9. Furtado MR, Callaway DS, Phair JP, et al. Persistence of HIV-1 transcription in peripheral-blood mononuclear cells in patients receiving potent antiretroviral therapy. N Engl J Med 1999; 340:1614-22.
10. 10. Zhang L, Ramratnam B, Tenner-Racz K, et al. Quantifying residual HIV-1 replication in patients receiving combination antiretroviral therapy. N Engl J Med 1999; 340:1605-13.
11. 11. Stellbrink HJ, van Lunzen J, Hufert FT, et al. Asymptomatic HIV infection is characterized by rapid turnover of HIV RNA in plasma and lymph nodes but not of latently infected lymph-node CD4 T cells. AIDS 1997; 11:1103-10.
12. 12. Lafeuillade A, Chollet L, Hittinger G, Profizi N, Costes O, Poggi C. Residual human immunodeficiency virus type 1 RNA in lymphoid tissue of patients with sustained plasma RNA of <200 copies/mL. J Infect Dis 1998; 177: 235-8.
13. 13. Wong JK, Gunthard HF, Havlir DV, et al. Reduction of HIV-1 in blood and lymph nodes following potent antiretroviral therapy and the virologic correlates of treatment failure. Proc Natl Acad Sci USA 1997; 94:12574-9.
14. 14. Cavert W, Notermans DW, Staskus K, et al. Kinetics of response in lymphoid tissues to antiretroviral therapy of HIV-1 infection. Science 1997; 276: 960-4.
15. 15. Ruiz L, van Lunzen J, Arno A, et al. Protease inhibitor-containing regimens compared with nucleoside analogues alone in the suppression of persistent HIV-1 replication in lymphoid tissue. AIDS 1999; 13:F1-8.
16. 16. Markowitz M, Vesanen M, Tenner-Racz K, et al. The effect of commencing combination antiretroviral therapy soon after human immunodeficiency virus type 1 infection on viral replication and antiviral immune responses. J Infect Dis 1999; 179:527-37.
17. 17. Tenner-Racz K, Stellbrink HJ, van Lunzen J, et al. The unenlarged lymph nodes of HIV-1 infected, asymptomatic patients with high CD4 T cell counts are sites for virus replication and CD4 T cell proliferation: the impact of highly active antiretroviral therapy. J Exp Med 1998; 187: 949-59.
18. 18. Lafeuillade A, Tamalet C, Poggi C, Pellegrino P, Tourres C, Izopet J. Antiretroviral effect of zidovudine-didanosine combination on blood and lymph nodes. AIDS 1997; 11:67-72.
19. 19. Gunthard HF, Wong JK, Ignacio CC, et al. Human immunodeficiency virus replication and genotypic resistance in blood and lymph nodes after a year of potent antiretroviral therapy. J Virol 1998; 72:2422-8.
20. 20. Fox C, Cottler-Fox M. In situ hybridization in HIV Research. J Microscop Tech Res 1993; 25:78-84.
21. 21. van Gemen B, van Beuningen R, Nabbe A, et al. A one-tube quantitative HIV-1 RNA NASBA nucleic acid amplification assay using electrochemiluminescent (ECL) labelled probes. J Virol Methods 1994; 49:157-67.
22. + T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy. Nat Med 1999; 5:651-5.
23. 23. Hertogs K, de Bethune MP, Miller V, et al. A rapid method for simultaneous detection of phenotypic resistance to inhibitors of protease and reverse transcriptase in recombinant human immunodeficiency virus type 1 isolates from patients treated with antiretroviral drugs. Antimicrob Agents Chemother 1998; 42:269-76.
24. 24. Pauwels R, Hertogs K, Kemo S, et al. Comprehensive HIV drug resistance monitoring using rapid, high-throughput phenotypic and genotypic assays with correlative data analysis [abstract]. In: Programs and abstracts of the 2nd International Workshop on Drug Resistance and Treatment Strategies (Lake Maggiore, Italy). London: International Medical Press, 1998.
25. 25. Lafeuillade A, Poggi C, Tamalet C, Profizi N. Human immunodeficiency virus type 1 dynamics in different lymphoid tissue compartments. J Infect Dis 1997; 176:804-6.
26. 26. Verbiest W, Schel P, Conant M, et al. An epidemiological prospective survey-assessing the prevalence of HIV-1 drug resistance in 230 HIV-1 positive anti-retroviral naive patients from USA [abstract]. In: Program and abstracts of the 3d International Workshop on HIV Drug Resistance, Treatment Strategies and Eradication (San Diego), London: International Medical Press, 1999.
27. 27. Wegner S, Mascola J, Baville A, et al. High frequency of anti-retroviral drug resistance in HIV-1 from recently infected therapy naive individuals. In: Program and abstracts of the 6th Conference on Retroviruses and Opportunistic Infections (Chicago). Alexandria, VA: Infectious Diseases Society of America, 1999.
28. 28. Pantaleo G, Graziosi C, Demarest JF, et al. HIV infection is active and progressive in lymphoid tissue during the clinically latent stage of disease. Nature 1993; 362:355-8.
29. 29. Embretson J, Zupancic M, Ribas JL, et al. Massive covert infection of helper T lymphocytes and macrophages by HIV during the incubation period of AIDS. Nature 1993; 362:359-62.
30. 30. Cavert W, Haase AT. A national tissue bank to track HIV eradication and immune reconstruction. Science 1998; 280:1865-6.
31. 31. Schrager LK, D'Souza MP. Cellular and anatomical reservoirs of HIV-1 in patients receiving potent antiretroviral combination therapy. JAMA 1998; 280:67-71.